Abstract

Simple SummaryLung cancer is the leading cause of cancer death worldwide. Detecting lung malignancies promptly is essential for any anticancer treatment to reduce mortality and morbidity, especially in high-risk individuals. The use of liquid biopsy to detect circulating biomarkers such as RNA, microRNA, DNA, proteins, autoantibodies in the blood, as well as circulating tumor cells (CTCs), can substantially change the way we manage lung cancer patients by improving disease stratification using intrinsic molecular characteristics, identification of therapeutic targets and monitoring molecular residual disease. Here, we made an update on recent developments in liquid biopsy-based biomarkers for lung cancer early diagnosis, and we propose guidelines for an accurate study design, execution, and data interpretation for biomarker development.Lung cancer burden is increasing, with 2 million deaths/year worldwide. Current limitations in early detection impede lung cancer diagnosis when the disease is still localized and thus more curable by surgery or multimodality treatment. Liquid biopsy is emerging as an important tool for lung cancer early detection and for monitoring therapy response. Here, we reviewed recent advances in liquid biopsy for early diagnosis of lung cancer. We summarized DNA- or RNA-based biomarkers, proteins, autoantibodies circulating in the blood, as well as circulating tumor cells (CTCs), and compared the most promising studies in terms of biomarkers prediction performance. While we observed an overall good performance for the proposed biomarkers, we noticed some critical aspects which may complicate the successful translation of these biomarkers into the clinical setting. We, therefore, proposed a roadmap for successful development of lung cancer biomarkers during the discovery, prioritization, and clinical validation phase. The integration of innovative minimally invasive biomarkers in screening programs is highly demanded to augment lung cancer early detection.

Highlights

  • Lung cancer is an aggressive disease accounting for ~380,000 deaths/year only in Europe (WHO; http://gco.iarc.fr; accessed on 21 April 2021) and ~2 million deaths/year worldwide

  • The drawback of LowDose Computed Tomography (LDCT) screening is the presence of uncertainties about high costs, risk of radiation exposure, and false positives observed in the screening population [7], which may obstacle a fully safe large scale implementation of the LDCT screening for lung cancer in Europe [8]

  • We reviewed the literature for the most promising biomarkers and relevant technical issues, of which here we present a summary with the aim to propose guidelines for an accurate study design and execution, and data interpretation for biomarker development

Read more

Summary

Introduction

Lung cancer is an aggressive disease accounting for ~380,000 deaths/year only in Europe (WHO; http://gco.iarc.fr; accessed on 21 April 2021) and ~2 million deaths/year worldwide. Detecting lung malignancies promptly is essential for any anticancer treatment to reduce mortality and morbidity, especially in high-risk individuals [4]. Lung Screening Trial (NLST) and other non-randomized trials [5] demonstrated that LowDose Computed Tomography (LDCT) screening can reduce mortality (~20%). The drawback of LDCT screening is the presence of uncertainties about high costs, risk of radiation exposure, and false positives observed in the screening population [7], which may obstacle a fully safe large scale implementation of the LDCT screening for lung cancer in Europe [8]. The false-positive rate is problematic, as suspicious nodules may require invasive investigations, causing unnecessary morbidity and reduced acceptance of screening among at-risk individuals. The integration of LDCT screening with innovative cancer biomarkers analyzable through minimally invasive approaches aimed to increase screening accuracy is highly demanded

Methods
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call